NADH for PARKINSON'S
A New Therapeutic Approach
for Treating PARKINSON'S DISEASE NUTRITIONALLY
Birkmayer JGD, Vrecko C, Volc D, Birkmayer W.
Nicotinamide adenine dinucleotide (NADH) -
a new therapeutic approach to Parkinson’s disease
Comparison of oral and parental application.
Acta Neurol Scand 1993: 87: Suppl 146; 32-35.
- Clinical research
Birkmayer-Institut fur Parkinsontherapie, Schwarzpanierstrasse 15, A-1090
- Dr. G.D.Birkmayer with Birkmayer-Institut for Parkinsontherapie in Vienna, Austria
- Dr. D.Volc with Birkmayer-Institut for Parkinsontherapie in Vienna, Austria
- Dr. W. Birkmayer with Birkmayer-Institut for Parkinsontherapie in Vienna, Austria
- Dr. C.Vrecko with Department of Medical Chemistry, University of Graz, Graz, Austria
My Dosage to be taken at 3 am on empty stomach with extra water:
20 grams NADH with 200 mg CoQ10 and 300 mg of R-Alpha Lipoic Acid.
See additional Nutritional Supplement
upon request by email to FoTL8887@gmail.com.
The reduced coenzyme nicotinamide adenine dinucleotide (NADH) has been used as medication in 885 parkinsonian patients in an open label trial. About half of the patients received NADH by intravenous infusion, the other
part orally by capsules. In about 80 % of the patients a beneficial clinical effect
was observed: 19.3% of the patients showed a very good (30 - 50 %) improvement of
disability, 58.8% a moderate (10 - 30 %) improvement. 21.8 % did not respond to NADH. Statistical analysis of the improvement
in correlation with the disability prior to treatment, the duration of the disease and the age of the patients revealed
the following results: All these 3 parameters have a significant although weak influence on the improvement. The disability
before the treatment has a positive regression coefficient (t < 0.01). the duration of the disease has a negative regression
coefficient (< 0.01) and so has the age a negative regression coefficient (t< 0.05). In other words younger patients
and patients with a shorter duration of disease have a better change to gain a marked improvement than older patients and
patients with longer duration of the disease. The orally applied form of NADH yielded
an overall improvement in the disability was comparable to that of the parenterally
It is generally accepted that Parkinson’s disease is caused biochemically by a deficit of dopamine in the basal ganglia of the brain stem (1). The immediate precursor
of dopamine, L-DOPA, is able to substitute the shortage in dopamine (2), whereas tyrosine, a precursor of L-DOPA, is unable to do so. This indicates that the biosynthesis of dopamine is blocked at the metabolic
conversion from tyrosine to L-DOPA. The enzyme catalyzing this reaction is tyrosine hydroxylase
(TH) the activity of which is considerably diminished in substantia nigra of patients ( 3, 4 ).
Indirect evidence for the central role of TH in the biosynthesis of dopamine has been gained long ago by applying
(alpha) - methylparatyrosine, an inhibitor of TH, to parkinsonian patients. Under this medication the disability of the
patients deteriorated indicating a further reduced L-DOPA biosynthesis ( 5
). In 1981 Nagatsu and coworkers ( 6 ) showed that H4 biopterin, the coenzyme of TH, is reduced to about 50% in the brain of parkinsonian
patients in comparison to that of age matched healthy control. This may be one of the reasons for the reduced TH
For the time being the first choice of therapy
is till substitution by L-DOPA which is the end product of TH and readily converted into dopamine. L-DOPA is known to act
as feedback inhibitor of TH ( 7 ). Thus the exogenous supplied L-DOPA
will inhibit TH activity already reduced in parkinsonian patients even further. Taking this account we considered a new concept to overcome the dopamine deficit namely to stimulate TH activity in order
to increase L-DOPA biosynthesis. This may be accomplished by adding the reduced
or missing cofactors. Since we know that the coenzyme of TH H4biopterin is also reduced in the brain of parkinsonian patients,
therapeutic application of this substance was considered. However, clinical trial with H4biopterin did not show any beneficial
clinical effect with Parkinsonian patients ( 8, 9 ). The failure of
this approach was the impermeability of the blood brain barrier for H4biopterin. Therefore, this substance cannot reach
its target, the substantia nigra in the brain. The question was whether it is possible
to stimulate the H4 biopterin biosynthesis in the brain. The H4 biopterin deficiency could be due either to a decreased
biosynthesis or to a lack in the biological active form. If a diminished biosynthesis of H4 biopterin is the cause of TH
defect, stimulation of H4 biopterin biosynthesis should elevate the enzyme activity. The key
enzyme in H4 biopterin biosynthesis is the quinoidH2pteridin reductase ( 10
). This enzyme needs the reduced nicotinamide adenine dinucleotide (NADH)
as coenzyme. Our idea was to stimulate H4 biopterin biosynthesis by applying NADH which increases the quinonoid H2 pteridine reductase activity
and due to this amount of H4 biopterin increases. Owing to this NADH may stimulate endogenous L-DOPA biosynthesis
by the postulate mechanism. An increase in L-DOPA production should be reflected by an improvement of the clinical symptoms
of parkinsonian patients. In order to investigate our concept in more detail more than 800 parkinsonian patients have been
treated with NADH and the possible mechanism of action of NADH has been studied in a dopamine producing neuroblastoma cell-line.
A New Therapeutic Approach for Treating PARKINSON'S
MATERIALS AND METHODS:
an open label trial 885 parkinsonian patients have been treated with the coenzyme. Diagnosis and disability scores of parkinsonian
patients were established according to the scale of Birkmayer and Neumayer ( 11
NADH (synonyms: Beta-NADH, Reduced DPN, Beta
DPNH) was obtained from Boehringer Mannheim. 12.5 mg of NADH were dissolved in 100
ml 0.9 percent sterile sodium chloride, buffered, pH 7.6, filtered through a 0.22 micron Millipore filter and intravenously
infused in 30 minutes. NADH solutions were prepared always fresh immediately prior to use. One group of patients received
NADH infusion every other day. The other group of patients obtained 5 mg NADH orally in the form of capsules. Treatment
was given every other day for 14 days. The disability score was determined before the first NADH treatment and after the
last NADH treatment RESULTS:
885 patients were included in this study.
- 42 patients (4.7 %) showed a 50 % improvement in disability,
(6.1 %) a 40 % improvement,
- 75 (8.4 %) a 30 % improvement,
- 147 (16.6
%) a 20 % improvement
- 374 (42.2 %) a 10 % improvement.
- 193 (21.8 %)
did not respond to NADH.
When the 415 patients
receiving NADH intravenously were compared with those 470 persons getting the oral form of NADH the mean value of improvement
in disability after i.v. applied NADH was 20.6 % after orally applied NADH 19.8 % (Table 1). These findings
indicate that the oral form of NADH shows a beneficial clinical effect comparable
to that of the iv. applied NADH not only in the mean value but also in the maximum value. The maximum improvement
of i.v. applied NADH was 55 %, the maximum of orally applied NADH 60 %. The motoric ability improved considerably in these
patients, in particular the walking, pushing, posture and speech as well as mimic.
After withdrawal of NADH from the usual medication, a worsening of the patient’s disability was observed in
between 2 - 3 weeks. This indicated the improvement of the symptoms to be caused by the NADH applied. In order to substantiate
whether NADH is able to stimulate L-DOPA biosynthesis we tested this substance in
tissue culture. When neuroblastoma cells were incubated with NADH a dosage dependent increase in dopamine production was
observed. In the presence of 200 micro-grams NADH a four fold increase in dopamine production was observed. This stimulation
was independent from the tyrosine supplied exogenously indicating that the substrate tyrosine is not the limiting factor but the enzyme or the coenzyme, respectively.
The stimulation of dopamine production increased with the number
of cells. In the presence of 200 micro-grams of NADH/ ml 20 million cells yielded 12 nano-grams of dopamine/ ml, 40 million
cells 44 nano-grams dopamine/ml and 60 million cells 72 nano-grams despectively.which was in most cases 14 days from the
beginning of the therapy.
When TH activity was
measured directly after NADH had been added to the culture medium, a 75 % increase could be observed. This finding indicates
that NADH is able to stimulate TH activity directly. A positive correlation between duration of the disease and disability
before treatment appears to be most plausible.
to this one might expect that both high age and long duration of the disease coincide with a marked improvement. However,
a refined statistical analysis ends up with the contrary, meaning that a negative correlation between age and improvement
of the treatment as well between duration of the disease and improvement after treatment is obtained. For an accurate assessment
of the real relationship between these variables (disability before treatment, age, duration of disease and improvement)
it is necessary to subtract the effects of the variable disability before treatment. The results of this calculation show
that in general younger patients and patients with a shorter duration of disease respectively have a better chance to gain
a marked improvement than older patients and patients with a longer duration of the disease.
Therapeutic Approach for Treating PARKINSON'S DISEASE
study confirms and extends our previous reports on the clinical benefit of NADH for parkinsonian patients ( 12,
13, 14). The new finding of this report is that the oral form of NADH shows a beneficial clinical
effect comparable to that of the intravenously applied NADH.
The galenic formulation of the oral form of NADH is a critical factor with regard
to its clinical efficacy.NADH into the acid condition of the stomach. Since
NADH is rapidly oxidized below pH 7.6 the conditions in the stomach will inactivate NADH by converting it to NAD+.
The investigations of this report were therefore performed with NADH capsules coated with an acid-stable film and a release time of 2 - 3 hours. With this galenic formulation
of NADH an improvement in disability
When we first
used NADH filled in gelatin capsules the effect was not convincing. This was most likely due to the rapid dissolution (
approximately 10 - 15 minutes) of the capsules leading to a release of could be achieved which was comparable to that of
intravenously applied NADH. It should be pointed out that most of the patients included in this study received in addition
to NADH the classical medication such as Madopar or Sinemet with or without addition, such as deprenyl, bromocryptine or
amantadine. In many of these patients the daily dose of L-DOPA could be reduced considerably. In some patients it could
be omitted totally.
The question is whether or not the well
established L-DOPA therapy should be replaced by NADH treatment. Arguments in favor of the new NADH treatment become apparent
when the biochemical and pharmacological differences behind these 2 therapeutic concepts are considered. The L-DOPA therapy
follows the principle of substitution meaning that dopamine deficit is filled up by substituting with its immediate precursor
L-DOPA. However, as we know, substitution of certain biological substances by exogenous supply will lead to a depression
of the organism’s own biosynthesis. This holds for cortisone, thyroxine, aldosterone, many other hormones and metabolic
substances. It is certainly valid also for L-DOPA biosynthesis. In other words exogenous
supply of L-DOPA will inhibit its endogenous biosynthesis. As already mentioned the L-DOPA producing enzyme, TH, is considerably
reduced in parkinsonian patients ( 3,
4 ). It is also known that TH is inhibited
by its end product L-DOPA ( 7, 15 ). This implies that TH working already insufficiently is further inhibited by the exogenous supplied L-DOPA. A further
reduction in enzymatic activity will be the consequence. Whether or not this is the cause of the frequent observed
"off" - effect, in particular after long - term treatment with L-DOPA, remains to be elucidated. The NADH therapy
on the other hand follows an opposite strategy, namely the stimulation of the endogenous L-DOPA biosynthesis by activation
of the key enzyme TH. There are a number of arguments in favor with NADH treatment
one of which is that patients which do not respond to the classical L-DOPA therapy even if higher dosages are applied, show
an improvement after NADH treatment.
stimulation of L-DOPA biosynthesis may occur via enhanced production of the TH coenzyme H4 biopterin. As shown
by Nagatsu and coworkers the levels of H4 biopterin in the brain and cerebrospinal
fluid of Parkinsonian patients are reduced about 50 % in comparison to that
of age matched healthy individuals. The cause of this H4 biopterin deficiency is still obscure. If the deficit in H4 biopterin
is due to a decreased biosynthesis, the biochemical mechanism of the NADH action may be explainable.
H4 biopterin is formed from H2pterin by an enzyme called quinoiddihydropteridinreductase
(DHPR), an enzyme which needs NADH as essential cofactor ( 10 )
There is indirect evidence that DHPR
influences TH activity via H4 biopterin because substances which competitively inhibit DHPR such as 1-methyl-4-phenyl-1,2,3,6
tetrahydropyridine (MPTP) induce parkinsonian symptoms ( 16 ).
A valid argument
for clinical efficacy of NADH as stimulation of L-DOPA biosynthesis would
be the measurement of an increase of L-DOPA concentration in the brain, in particular in substantia nigra. For obvious reasons it is impossible to gain these data because nobody,
for the time being, is able to measure the L-DOPA concentration in the substantia nigra directly before and after NADH treatment.
Therefore we have to rely on indirect evidence one of which is the metabolic product of dopamine and homovanillinic acid
(HVA) respectively. The level of this substance increases after NADH treatment parallel to the improvement in disability.
Furthermore by tissue culture experiments using dopamine producing neuroblastoma cells we were able to show that NADH is able to increase the production of dopamine. Furthermore
NADH does stimulate the enzymatic activity of TH directly when added to the culture medium.
These findings indicate that NADH acts
directly on TH due to this stimulates dopamine biosynthesis which is a considerable support for our clinical concept of
stimulation the endogenous dopamine production. It may be argued that the beneficial clinical effect observed under NADH
medication is not a central nervous system related but a peripheral one. If this is actually the case an increase in L-DOPA
in the blood will be the consequence. From this amount a certain percentage will reach the brain by potentially the same
mechanism by which exogenously supplied L-DOPA reaches the brain. Indirect evidence
for this assumption is derived from the observation that a DOPA decarboxylase inhibitor such
as carbidopa, given to a number of patients in
combination with NADH yielded a better and longer lasting clinical improvement than NADH alone.
The new therapeutic principle for treating Parkinson’s disease, namely the stimulation of the endogenous L-DOPA
biosynthesis, could overcome the drawback of the L-DOPA treatment in the sense that
it could avoid further destruction of the residual nigra cells caused by the action of radicals
which are formed in considerable quantities by auto-oxidation of L-DOPA. A double-blind study is in progress in our
Institute which will provide a definite conclusion about the clinical efficacy of this essential autosomal substance as
new therapeutic concepts for Parkinson’s disease.